NCT02819557View on ClinicalTrials.gov

Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 9, 2016

Primary Completion Date

February 9, 2018

Study Completion Date

February 9, 2018

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Ataluren

White to off-white powder for oral suspension.

Trial Locations (6)

32561

Child Neuro NWF, Gulf Breeze

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60612

Rush University Medical Center, Chicago

84112

University of Utah, Salt Lake City

02115

Children's Hospital Boston, Boston

75390-8843

Children's Medical Center Dallas, Dallas

Sponsors

Lead Sponsor

PTC Therapeutics
All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY

NCT02819557 - Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter